1.
Bioorg Med Chem Lett
; 19(9): 2599-603, 2009 May 01.
Article
in English
| MEDLINE
| ID: mdl-19332369
ABSTRACT
We describe the medicinal chemistry programme that led to the identification of the EP(1) receptor antagonist GSK269984A (8h). GSK269984A was designed to overcome development issues encountered with previous EP(1) antagonists such as GW848687X and was found to display excellent activity in preclinical models of inflammatory pain. However, upon cross species pharmacokinetic profiling, GSK269984A was predicted to have suboptimal human pharmacokinetic and was thus progressed to a human microdose study.